Vensana Capital has raised $225m for the final close of its maiden MedTech fund, supported by healthcare-focused VC Versant Capital.
Vensana Capital I will seek to back clinical development and commercial stage companies operating in MedTech sub-sectors such as medical devices, diagnostics, data science, drug delivery, digital health, and tech-enabled services.
Vensana and Versant have planned to collaborate on investment opportunities that cross over the biotechnology and MedTech sectors.
The firm was launched this year by former Versant Capital managing director Kirk Nielsen and former NEA partner Justin Klein.
“We are grateful for the trust and confidence of our limited partners, and for the support of the Versant team, in launching Vensana Capital,” said Nielsen.
“Medtech will continue to play a critical role in the healthcare system of the future, and we are excited to partner with entrepreneurs whose innovations will improve outcomes and lower the cost of care.”
Following the fund close, Nielsen will continue to manage his exiting MedTech portfolio companies backed by Versant funds.
Versant closed its latest biotech-focused fund, Versant Venture Capital VII, on $600m of commitments in December 2018.
Copyright © 2019 AltAssets